In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placeb
On the blog today I share how I like to curate authenticity on my Instagram feed when I have nothing ready to post. I want my feed to look nice and ‘in brand’ but I also want to focus on sharing this game of value as well. I’ve switched from...